New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based therapies for primary mitochondrial and severe renal diseasesHAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global ...